Scarica l'app Stockscreener
2.28
1.79%
0.04
Dopo l'orario di chiusura:
2.30
0.02
+0.88%
Precedente Chiudi:
$2.24
Aprire:
$2.27
Volume 24 ore:
1,965
Relative Volume:
0.09
Capitalizzazione di mercato:
$159.43M
Reddito:
-
Utile/perdita netta:
$-28.95M
Rapporto P/E:
-7.125
EPS:
-0.32
Flusso di cassa netto:
$-29.35M
1 W Prestazione:
-2.15%
1M Prestazione:
+0.00%
6M Prestazione:
-8.43%
1 anno Prestazione:
-28.75%
Intervallo 1D:
$2.217
$2.30
Intervallo di 1 settimana:
$2.20
$2.34
Portata 52W:
$1.75
$3.40
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Nome
Alpha Tau Medical Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-04-08 | Iniziato | Piper Sandler | Overweight |
| 2022-04-04 | Iniziato | Citigroup | Buy |
Alpha Tau Medical Ltd Borsa (DRTS) Ultime notizie
MasterCraft Boat Holdings, Inc. (NASDAQ:MCFT) Receives $19.20 Average Target Price from Analysts - Defense World
Spire Global, Inc. (NYSE:SPIR) Receives $13.67 Average Target Price from Brokerages - Defense World
Brokerages Set Silvaco Group, Inc. (NASDAQ:SVCO) PT at $20.83 - Defense World
Analysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) PT at $34.60 - Defense World
Orthofix Medical (NASDAQ:OFIX) and Alpha Tau Medical (NASDAQ:DRTS) Financial Contrast - Defense World
Comparing Alpha Tau Medical (NASDAQ:DRTS) and Beyond Air (NASDAQ:XAIR) - Defense World
Discover Alpha Tau Medical And 2 Other US Penny Stocks - Simply Wall St
Head-To-Head Review: Biotricity (NASDAQ:BTCY) vs. Alpha Tau Medical (NASDAQ:DRTS) - Defense World
HC Wainwright Reiterates "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Alpha Tau Joins FDA Program to Advance Cancer Therapy - TipRanks
Alpha Tau Announces Acceptance Into FDA’s Total Product - GlobeNewswire
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme - Yahoo Finance
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) Stock Rating Reaffirmed by HC Wainwright - Defense World
Alpha Tau Medical shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada
Alpha Tau’s Alpha DaRT Advances Lung Cancer Treatment - Yahoo Finance
HC Wainwright Reaffirms "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Alpha Tau Medical shares maintain Buy rating from H.C. Wainwright - Investing.com
Alpha Emitter Market Size to witness nearly $1751.5 Million By 2032 - 대구포스트
Alpha Tau treats first lung cancer patient with radiation therapy in Jerusalem - Mugglehead
Alpha Tau Treats First Patient with Recurrent Lung Cancer - ForexTV.com
Alpha Tau Medical Ltd. Treats First Patient with Recurrent Lung Cancer - Marketscreener.com
Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer - Marketscreener.com
Radiopharmaceutical Market 2024 – Industry Opportunities, Challenges, Value Chain and Sales Channels Analysis 2032 | Clarity Pharmaceuticals - 대구포스트
Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Expands By 23.9% - MarketBeat
Alpha Emitter Market Outlook, Key Trends and Growth Projections from 2024 to 2032 - 대구포스트
Alpha Emitter Market on the Rise: A Study on its Growth Prospects - openPR
Point72 DIFC Ltd Acquires Shares of 18,774 ChampionX Co. (NASDAQ:CHX) - Defense World
Alpha Tau Medical Ltd.FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT in Immunocompromised Patients with Recurrent cSCC - Marketscreener.com
FDA approves study of Alpha Tau’s Alpha DaRT for recurrent cSCC treatment - Yahoo Finance
Global Alpha Emitter Market Set to Reach $ 1751.5 Million by 2032, Expanding at 11.25% CAGR - 대구포스트
Alpha Tau’s Alpha DaRT Gains FDA Study Approval - TipRanks
Alpha Tau Medical Ltd. Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT in Immunocompromised Patients with Recurrent cSCC - Marketscreener.com
Alpha Tau Announces FDA Approval of IDE to Initiate - GlobeNewswire
Sidoti Events, LLC's Virtual September Small-Cap Conference - Yahoo Finance
Alpha Tau Medical Share PriceDRTS, RNS News, Articles, Quotes, & Charts (NASDAQ:DRTS) - Proactive Investors Australia
Alpha Tau Medical’s Alpha DaRT Technology Shows Breakthrough Results in Cancer Trials - Proactive Investors Australia
23,323 Shares in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Purchased by Caprock Group LLC - Defense World
Alpha Tau Medical (NASDAQ:DRTSW) Trading Down 5.3% - Defense World
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Up 63.4% in August - MarketBeat
Top 230+ startups in Radiation Therapy Devices in Sep, 2024 - Tracxn
Radiotherapy Devices Market Scope In The New Analysis By Leading Research Firm - WhaTech
Kromek Group (LON:KMK) Share Price Passes Below 200-Day Moving Average of $6.56 - Defense World
Aptus Capital Advisors LLC Raises Holdings in Alpha Tau Medical Ltd. (NASDAQ:DRTS) - Defense World
Aptus Capital Advisors LLC Sells 1,326 Shares of JPMorgan Municipal ETF (BATS:JMUB) - Defense World
Medical Lasers Market 2024: Exploring Industry Demand, Technological Advancements, And Future Prospects - WhaTech
Oncology Devices Market Key Trends, Latest Insights, Future Trends And Forecast To 2033 - WhaTech
DRTS: Company Seeks to Develop Significant Advance in Cancer Therapy with Alpha DaRT - Yahoo Finance
Financial Comparison: Assure (NASDAQ:IONM) versus Alpha Tau Medical (NASDAQ:DRTS) - Defense World
HP Inc. (NYSE:HPQ) Shares Sold by Cambridge Investment Research Advisors Inc. - Defense World
Alpha Tau Medical Ltd Azioni (DRTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):